Cargando…
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angi...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860/ https://www.ncbi.nlm.nih.gov/pubmed/27117754 http://dx.doi.org/10.1038/srep25195 |
_version_ | 1782429116767666176 |
---|---|
author | Giampieri, Riccardo Salvatore, Lisa Del Prete, Michela Prochilo, Tiziana D’Anzeo, Marco Loretelli, Cristian Loupakis, Fotios Aprile, Giuseppe Maccaroni, Elena Andrikou, Kalliopi Bianconi, Maristella Bittoni, Alessandro Faloppi, Luca Demurtas, Laura Montironi, Rodolfo Scarpelli, Marina Falcone, Alfredo Zaniboni, Alberto Scartozzi, Mario Cascinu, Stefano |
author_facet | Giampieri, Riccardo Salvatore, Lisa Del Prete, Michela Prochilo, Tiziana D’Anzeo, Marco Loretelli, Cristian Loupakis, Fotios Aprile, Giuseppe Maccaroni, Elena Andrikou, Kalliopi Bianconi, Maristella Bittoni, Alessandro Faloppi, Luca Demurtas, Laura Montironi, Rodolfo Scarpelli, Marina Falcone, Alfredo Zaniboni, Alberto Scartozzi, Mario Cascinu, Stefano |
author_sort | Giampieri, Riccardo |
collection | PubMed |
description | Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angiogenesis and thus potentially influence outcome during anti-angiogenesis treatment such as regorafenib. Aim of our study was to evaluate the role of VEGF and VEGFR genotyping in determining clinical outcome for colorectal cancer patients receiving regorafenib. We retrospectively collected clinical data and samples (tumour or blood) of 138 metastatic colorectal cancer patients treated with regorafenib. We analysed the correlation of different VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs) with patients’ progression-free survival (PFS) and overall survival (OS). Results from angiogenesis genotyping showed that only VEGF-A rs2010963 maintained an independent correlation with PFS and OS. Among clinical factors only ECOG PS was independently correlated with OS, whereas no correlation with PFS was evident. Grouping together those results allowed further patients stratification into 3 prognostic groups: favourable, intermediate and unfavourable. VEGF-A rs2010963 genotyping may represent an important tool for a more accurate selection of optimal candidates for regorafenib therapy. |
format | Online Article Text |
id | pubmed-4846860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48468602016-05-04 Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients Giampieri, Riccardo Salvatore, Lisa Del Prete, Michela Prochilo, Tiziana D’Anzeo, Marco Loretelli, Cristian Loupakis, Fotios Aprile, Giuseppe Maccaroni, Elena Andrikou, Kalliopi Bianconi, Maristella Bittoni, Alessandro Faloppi, Luca Demurtas, Laura Montironi, Rodolfo Scarpelli, Marina Falcone, Alfredo Zaniboni, Alberto Scartozzi, Mario Cascinu, Stefano Sci Rep Article Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and the severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms of VEGF and its receptor (VEGFR) genes might regulate angiogenesis and thus potentially influence outcome during anti-angiogenesis treatment such as regorafenib. Aim of our study was to evaluate the role of VEGF and VEGFR genotyping in determining clinical outcome for colorectal cancer patients receiving regorafenib. We retrospectively collected clinical data and samples (tumour or blood) of 138 metastatic colorectal cancer patients treated with regorafenib. We analysed the correlation of different VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs) with patients’ progression-free survival (PFS) and overall survival (OS). Results from angiogenesis genotyping showed that only VEGF-A rs2010963 maintained an independent correlation with PFS and OS. Among clinical factors only ECOG PS was independently correlated with OS, whereas no correlation with PFS was evident. Grouping together those results allowed further patients stratification into 3 prognostic groups: favourable, intermediate and unfavourable. VEGF-A rs2010963 genotyping may represent an important tool for a more accurate selection of optimal candidates for regorafenib therapy. Nature Publishing Group 2016-04-27 /pmc/articles/PMC4846860/ /pubmed/27117754 http://dx.doi.org/10.1038/srep25195 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Giampieri, Riccardo Salvatore, Lisa Del Prete, Michela Prochilo, Tiziana D’Anzeo, Marco Loretelli, Cristian Loupakis, Fotios Aprile, Giuseppe Maccaroni, Elena Andrikou, Kalliopi Bianconi, Maristella Bittoni, Alessandro Faloppi, Luca Demurtas, Laura Montironi, Rodolfo Scarpelli, Marina Falcone, Alfredo Zaniboni, Alberto Scartozzi, Mario Cascinu, Stefano Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title_full | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title_fullStr | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title_full_unstemmed | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title_short | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
title_sort | angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846860/ https://www.ncbi.nlm.nih.gov/pubmed/27117754 http://dx.doi.org/10.1038/srep25195 |
work_keys_str_mv | AT giampieririccardo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT salvatorelisa angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT delpretemichela angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT prochilotiziana angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT danzeomarco angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT loretellicristian angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT loupakisfotios angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT aprilegiuseppe angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT maccaronielena angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT andrikoukalliopi angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT bianconimaristella angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT bittonialessandro angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT faloppiluca angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT demurtaslaura angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT montironirodolfo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT scarpellimarina angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT falconealfredo angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT zanibonialberto angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT scartozzimario angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients AT cascinustefano angiogenesisgenotypingandclinicaloutcomeduringregorafenibtreatmentinmetastaticcolorectalcancerpatients |